Lupus Science & Medicine™
Lupus Science & Medicine™ is a peer-reviewed, open access, online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases.
It is the first lupus-specific open access journal in the world and was developed in response to the need for a barrier-free forum for publication of groundbreaking lupus studies. Lupus Science & Medicine™ is owned by the Lupus Foundation of America and published by BMJ, a respected global provider of evidence-based medical knowledge.
Research on lupus will be considered from fields including, but not limited to, rheumatology, dermatology, nephrology, immunology, pediatrics, cardiology, hepatology, pulmonology, obstetrics and gynecology, and psychiatry. Submissions from groups of investigators engaged in international collaborations are especially encouraged.Submit Now
New articles are added year-round so the online content always includes the latest developments in lupus research and treatment.
Articles cover the latest developments from basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases.
Want to know about the hottest topics in lupus research? Check out the list of 'most read articles' on Lupus Science & Medicine™.
2019 vs. 2018 Growth Statistics
Growth in Online Usage
Increase in Users Accessing Content
Number of Online Mentions for Content
Lupus Science & Medicine™ is edited by Jill P. Buyon, Division Director of Rheumatology, Professor of Medicine at New York University School of Medicine; and Ronald F. van Vollenhoven, Professor and Chief, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden. The journal has also assembled a world-class team of associate editors and an editorial board to maintain the journal's high standards, high visibility, and credibility.
Lupus Science & Medicine™ complements the Lupus Foundation of America’s national research program, which pursues an aggressive agenda to tackle the biggest challenges in lupus and find answers to the most important questions.